Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miriam Alb

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Immunotoxicology|December 10, 2024
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway conceptMiriam Alb, Kristin Reiche, Michael Rade, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation modelsEmmanuel Donnadieu, Maik Luu, Miriam Alb, et al.
Cancer Cell|December 5, 2025
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaMichael Rade, David Fandrei, Markus Kreuz, et al.
Blood Cancer Discovery|March 26, 2026
Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel TherapySofie-Katrin Kadel, Lukas Scheller, Alexander M Leipold, et al.
NPJ Digital Medicine|August 1, 2025
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapiesUlrike Weirauch, Markus Kreuz, Colin Birkenbihl, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Immunotoxicology|December 10, 2024
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway conceptMiriam Alb, Kristin Reiche, Michael Rade, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation modelsEmmanuel Donnadieu, Maik Luu, Miriam Alb, et al.
Cancer Cell|December 5, 2025
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaMichael Rade, David Fandrei, Markus Kreuz, et al.
Blood Cancer Discovery|March 26, 2026
Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel TherapySofie-Katrin Kadel, Lukas Scheller, Alexander M Leipold, et al.
NPJ Digital Medicine|August 1, 2025
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapiesUlrike Weirauch, Markus Kreuz, Colin Birkenbihl, et al.
Pageof 3